Target: ATG9B.
Conjugate: ATTO 594.
Product Type: Polyclonal.
Immunogen: Synthetic peptide from the N-terminal of Human ATG9B (aa. 110-121).
Swiss-Prot: Q674R7.
Purification: Peptide Affinity Purified.
Storage Buffer: PBS, 50% glycerol, 0.09% sodium azide.
Concentration: 1 mg/ml.
Specificity: Detects ~100 kDa.
Cellular Localization: Cytoplasmic Vesicle, Autophagosome Membrane, Multi-Pass Membrane Protein.
Tissue Specificity: Highly expressed in placenta (trophoblast cells) and pituitary gland. Not expressed in vascular endothelial.
Scientific Background: ATG9B is involved in autophagy and cytoplasm to vacuole transport (Cvt) vesicle formation. Plays a key role in the organization of the preautophagosomal structure/phagophore assembly site (PAS), the nucleating site for formation of the sequestering vesicle. Highly expressed in the placenta and the pituitary gland.
References: 1. http://www.uniprot.org/uniprot/Q674R7.
Field of Use: Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.
English
Deutsch
